Challenges and solutions to embed cancer survivorship research and innovation within the EU Cancer Mission.
EU Cancer Mission
Europe's Beating Cancer Plan
cancer survivorship
living with and beyond cancer
survivorship research
Journal
Molecular oncology
ISSN: 1878-0261
Titre abrégé: Mol Oncol
Pays: United States
ID NLM: 101308230
Informations de publication
Date de publication:
07 2021
07 2021
Historique:
revised:
14
04
2021
received:
17
02
2021
accepted:
27
05
2021
pubmed:
31
5
2021
medline:
8
4
2022
entrez:
30
5
2021
Statut:
ppublish
Résumé
We have reached a watershed moment in Europe in our efforts to ensure increased survival and better outcomes for cancer patients. The EU Cancer Mission and the European Beating Cancer Plan together provide an unrivalled opportunity to make significant inroads into a disease that kills over 1.7 million European citizens annually. Harnessing these twin pillars of cancer research and cancer control can be transformative for the European cancer community and in particular for the European cancer patient. However, from a research perspective, in order to fully realise these benefits, we need to ensure that all aspects of the cancer continuum are addressed. Previous research efforts have focussed more on the diagnosis and treatment of cancer, whereas cancer survivorship, to date, has been overlooked. Here, we aim to redress this balance, by identifying the key challenges in cancer survivorship research that need to be addressed and proposing a series of recommended solutions, which, if acted upon, would deliver significant benefits for the nearly 20 million cancer survivors in Europe. To achieve this, we propose the development of a clearly articulated and sustainably funded European Cancer Survivorship Research and Innovation Plan. Embedding this plan within the framework of the EU Cancer Mission would be transformative for cancer survivors and society.
Identifiants
pubmed: 34053182
doi: 10.1002/1878-0261.13022
pmc: PMC8253087
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1750-1758Informations de copyright
© 2021 The Authors. Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.
Références
Lancet Oncol. 2017 Nov;18(11):e622-e623
pubmed: 29208378
Eur J Cancer. 2020 Jun;132:98-99
pubmed: 32335477
Lancet Oncol. 2014 Mar;15(3):258-60
pubmed: 24503530
Mol Oncol. 2019 Mar;13(3):624-635
pubmed: 30552794
Lancet Oncol. 2019 Nov;20(11):1482-1485
pubmed: 31674308
Lancet Oncol. 2014 Jan;15(1):23-34
pubmed: 24314615
Mol Oncol. 2020 Aug;14(8):1589-1615
pubmed: 32749074
ESMO Open. 2017 Jan 6;1(6):e000127
pubmed: 28848664
J Clin Oncol. 2018 Jul 20;36(21):2223-2230
pubmed: 29874138
Int J Epidemiol. 2020 Oct 1;49(5):1517-1525
pubmed: 32984907
Mol Oncol. 2019 Mar;13(3):502-510
pubmed: 30657635
Eur J Cancer. 2018 Oct;102:69-81
pubmed: 30138773